Janssen’s Invokana is an oral medicine indicated to decrease blood sugar in type 2 diabetes patients. Credit: Bic.

Janssen Pharmaceutical has received approval from the US Food and Drug Administration (FDA) for the use of Invokana (canagliflozin) to minimise the risk of major adverse cardiovascular (CV) events in adults.

The indication covers CV events such as heart attack, stroke or death in patients with type 2 diabetes (T2D) and have a known CV condition.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Invokana is an oral, prescription medicine to decrease blood sugar (glucose) in adults with T2D. The drug must be used along with diet and exercise.

Janssen said that the FDA decision comes after the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE) released reports supporting Invokana use.

“This FDA approval makes Invokana the only oral type 2 diabetes treatment indicated to reduce the risk of heart attack, stroke or CV death.”

Janssen Research & Development cardiovascular and metabolism global therapeutic area head James List said: “This FDA approval makes Invokana the only oral type 2 diabetes treatment indicated to reduce the risk of heart attack, stroke or CV death.

“Not only does Invokana enable patients to control their diabetes symptoms by lowering their A1C levels, but it now also helps protect them from potentially devastating cardiovascular events.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Invokana’s effect on CV risk was assessed in the CANVAS Program that involved a total of more than 10,000 adults with T2D and established CV disease or at risk for the disease with two or more risk factors.

Overall data showed that the drug in combination with standard of care led to a 14% decrease in the combined risk of heart attack, stroke and CV death, compared to placebo.

For participants with established CV disease, Invokana reduced the combined risk of heart attack, stroke and CV death by 18%.